Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Drug Delivery

Bayer's Eylea wins approval in Europe to treat retinal vein occlusion By PBR Staff Writer
German pharmaceutical firm Bayer HealthCare has received approval from the European Commission for Eylea (aflibercept solution for injection into the eye) to treat patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
Drug Research > Drug Delivery > News
Amgen reports positive results from Phase III study of AMG 416 with cinacalcet By PBR Staff Writer
Amgen has reported that the head-to-head Phase III study comparing AMG 416 with cinacalcet has met endpoints in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis.
Drug Research > Drug Delivery > News Eisai's Phase III trial of sarcoma drug Halaven meets primary endpoint By PBR Staff Writer
Japanese pharmaceutical firm Eisai has reported positive results from its Phase III trial (Study 309) of Halaven (eribulin) in patients with soft tissue sarcoma.
Drug Research > Drug Delivery > News
See more Drug Delivery news

Latest Drug Delivery News and Insight

View all Drug Delivery news or find news targeted to your interests
Sanofi's diabetes drug Toujeo gets FDA approval
By PBR Staff Writer
Sanofi has received approval from the US Food and Drug Administration (FDA) for Toujeo (insulin glargine [rDNA origin] injection, 300U/mL), a once-daily long-acting basal insulin to improve glycemic control in adult patients with type 1 and type 2 diabetes.
Drug Research > Drug Delivery > News
Pfizer's Phase II trial of meningococcal group B vaccine meets co-primary immunogenicity objectives
By PBR Staff Writer
Pfizer has reported positive top-line results from a Phase II trial of Trumenba (Meningococcal Group B Vaccine) co-administered with routine meningococcal (A, C, Y, and W) (MCV4) and single-dose tetanus, diptheria and pertussis (Tdap) vaccines.
Drug Research > Drug Delivery > News
Valeo Pharma enters into distribution deal with Questcor for Synacthen Depot in Canada
By PBR Staff Writer
Specialty pharmaceutical firm Valeo Pharma has entered into an agreement with Questcor Pharmaceuticals, a subsidiary of Mallinckrodt, to distribute Synacthen Depot (cosyntropin zinc hydroxide injection) in Canada.
Drug Research > Drug Delivery > News
Agilvax, Humabs to develop targeted vaccines and immunotherapies
By PBR Staff Writer
US-based vaccine developer Agilvax has entered into a collaboration with Swiss-based Humabs BioMed to develop targeted vaccines and immunotherapies to combat diseases with unmet medical needs.
Drug Research > Drug Delivery > News
Adapt Pharma gets FDA fast track status for intranasal naloxone to treat opioid overdose
By PBR Staff Writer
US-based biopharmaceutical firm Lightlake Therapeutics' partner Adapt Pharma has received fast track designation from the US Food and Drug Administration (FDA) for intranasal naloxone treatment to reverse opioid overdose.
Drug Research > Drug Delivery > News
Teva launches generic Lovenox and Zyvox in US
By PBR Staff Writer
Teva Pharmaceutical Industries has launched the generic equivalent of Lovenox (enoxaparin sodium injection) in seven dosage strengths in the US.
Drug Research > Drug Delivery > News
Pfizer reports positive Phase III trial results of Type 1 Gaucher disease drug Elelyso
By PBR Staff Writer
Pfizer has reported positive results from its multi-center, extension Phase III trial evaluating the long-term efficacy and safety of Elelyso (taliglucerase alfa) for injection in pediatric patients with Type 1 Gaucher disease who were treatment-naïve or previously treated with imiglucerase.
Drug Research > Drug Delivery > News
Panacea, Accelovance team up to develop new cancer vaccine
By PBR Staff Writer
Panacea Pharmaceuticals and Accelovance have entered into a clinical development services agreement to develop and advance Panacea's new nanoparticle-based therapeutic cancer vaccine.
Drug Research > Drug Delivery > News
Pfenex, Hospira to develop and commercialize proposed biosimilar of Lucentis
By PBR Staff Writer
US-based biotechnology firm Pfenex has entered into an agreement with Hospira, a provider of injectable drugs and infusion technologies, to develop and commercialize Pfenex's drug candidate PF582.
Drug Research > Drug Delivery > News
Vaxxas secures equity funding of $20m to accelerate commercialization of new vaccine platform
Vaxxas, a biotechnology company commercializing a novel vaccination platform, announced it has secured equity funding of A$25m ($20m) from new and existing investors.
Drug Research > Drug Delivery > News
View all Drug Delivery news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250